[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370390-105":59,"doc-detail-370390-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","dna-methylation-predicted-plasma-protein-levels-and-breast-cancer-risk","DNA methylation-predicted plasma protein levels and breast cancer risk","","Blood DNA methylation (DNAm) profiles track changes in circulating leukocyte composition during breast cancer development, supporting peripheral immune alterations as potential risk markers. Prior work introduced DNAm-based predictors of plasma proteins (“Protein EpiScores”), yet their detailed links to breast cancer risk remain insufficiently characterized. This study evaluates associations between 109 Protein EpiScores derived from whole-blood DNAm and incident breast cancer using weighted Cox regression, including stratified analyses and timing effects.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dna-methylation-predicted-plasma-protein-levels-and-breast-cancer-risk/370390/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dna-methylation-predicted-plasma-protein-levels-and-breast-cancer-risk/370390.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main goal?","Question",{"text":112,"@type":113},"To test whether DNA methylation-predicted plasma protein levels (“Protein EpiScores”) are associated with breast cancer risk in detail, including timing and participant subgroups.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were Protein EpiScores generated and how many were analyzed?",{"text":117,"@type":113},"Whole-blood DNAm profiles were used to calculate 109 Protein EpiScores for women in a Sister Study case-cohort sample.",{"name":119,"@type":110,"acceptedAnswer":120},"Which Protein EpiScores showed positive versus inverse associations with invasive breast cancer risk?",{"text":121,"@type":113},"RARRES2, IGFBP4, and CCL21 were positively associated, while F7, SELL, CXCL9, CD48, and IL19 were inversely associated with invasive breast cancer risk.",{"name":123,"@type":110,"acceptedAnswer":124},"Did the associations vary by tumor subtype or diagnosis timing?",{"text":125,"@type":113},"Associations were stronger for estrogen receptor-negative tumors, and eight immune response-related Protein EpiScores were linked to invasive cancers diagnosed within five years of enrollment.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},370390,1790471927,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Kresovich etal. Breast Cancer Research (2025) 27:46 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-025-02004-x](https://doi.org/10.1186/s13058-025-02004-x)  \nRESEARCH Open Access  \nDNA methylation-predicted plasma protein levels and breast cancer risk  \nJacob K. Kresovich 1,2,3*, Brett M. Reid 1, Katie M. O’Brien3, Zongli Xu4, Doratha A. Byrd 1, Clarice R. Weinberg4, Dale P. Sandler3 and Jack A. Taylor3,5  \nAbstract  \nBackground Blood DNA methylation (DNAm) profiles have been used to show that changes in circulating leukocyte composition occur during breast cancer development, suggesting that peripheral immune system alterations are markers of breast cancer risk. Blood DNAm profiles have recently been used to predict plasma protein concentrations (“Protein EpiScores”), but their associations with breast cancer risk have not been examined in detail.  \nMethods Whole blood DNAm profiles were obtained for a case-cohort sample of participants in the Sister Study and used to calculate 109 Protein EpiScores. Of the 4,479 women included, 2,151 (48%) were diagnosed with breast cancer within 15 years of their baseline blood draw (median time to diagnosis: 8.6 years; 1,673 invasive cancer and 478 ductal carcinomas in situ) . Protein EpiScores associations with breast cancer incidence were estimated using weighted Cox regression models, overall and stratified by time and participant characteristics.  \nResults Protein EpiScores for RARRES2, IGFBP4, and CCL21 were positively associated with invasive breast cancer risk (hazard ratios from 1.17 to 1. 24), while those for F7, SELL, CXCL9, CD48, and IL19 were inversely associated (hazard ratios from 0.82 to 0 . 86) (all FDR \u003C 0. 10) . Eight immune response-related Protein EpiScores (CXCL9, CD48, FCGR3B, CXCL11, CCL21, CRTAM, VCAM1, GZMA) were associated with invasive cancers diagnosed within five years of enrollment. Protein EpiScore associations were consistently stronger for estrogen receptor-negative tumors. Conclusions Several Protein EpiScores, including many related to immune response, were associated with  \nbreast cancer risk, highlighting novel changes to the peripheral immune system that occur during breast cancer development.  \nKeywords Breast Cancer, DNA methylation, Proteomics, Epidemiology, Prospective cohort  \n*Correspondence:  \nJacob K. Kresovich  \n[jacob.kresovich@moffitt.org](jacob.kresovich@moffitt.org)  \n1Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA  \n2Department of Breast Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA  \n3Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, Durham, NC 27709, USA 4Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, Durham, NC 27709, USA  \n5Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, Durham, NC 27709, USA  \n© The Author(s) 2025, corrected publication 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercialNoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permiss","cbCaimbdFOZbRpwl","https://ap.wps.com/l/cbCaimbdFOZbRpwl","pdf",1466871,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the study’s main goal?\",\"answer\":\"To test whether DNA methylation-predicted plasma protein levels (“Protein EpiScores”) are associated with breast cancer risk in detail, including timing and participant subgroups.\"},{\"question\":\"How were Protein EpiScores generated and how many were analyzed?\",\"answer\":\"Whole-blood DNAm profiles were used to calculate 109 Protein EpiScores for women in a Sister Study case-cohort sample.\"},{\"question\":\"Which Protein EpiScores showed positive versus inverse associations with invasive breast cancer risk?\",\"answer\":\"RARRES2, IGFBP4, and CCL21 were positively associated, while F7, SELL, CXCL9, CD48, and IL19 were inversely associated with invasive breast cancer risk.\"},{\"question\":\"Did the associations vary by tumor subtype or diagnosis timing?\",\"answer\":\"Associations were stronger for estrogen receptor-negative tumors, and eight immune response-related Protein EpiScores were linked to invasive cancers diagnosed within five years of enrollment.\"}]","DNA methylation-predicted plasma protein levels and breast cancer risk | PDF",1790188283,25,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e442b902dc0d616538412c7c511b26a3.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/558176c4af0bdfa34fa9f31483999723.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c87b88509aeb67cde077ea4da135f1e.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e2cecf0929b8642a147fca217e773f9.webp",980,1306]